Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

Maria Apellaniz-Ruiz, Meta H. Diekstra, Juan M. Roldan, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H. J. Mathijssen, Jesse J. Swen, Stefan Bohringer, Jesus Garcia-Donas, Brian I. Rini, Henk-Jan Guchelaar, Cristina Rodriguez-Antona*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)227-231
Number of pages5
JournalPharmacogenetics and Genomics
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 2017

Keywords

  • advanced renal cell carcinoma
  • KDR
  • polymorphism
  • sunitinib
  • vascular endothelial growth factor receptor 2
  • SINGLE-NUCLEOTIDE POLYMORPHISMS
  • 1ST-LINE SUNITINIB
  • INDUCED TOXICITY
  • MARKERS
  • THERAPY
  • VEGFR2
  • IDENTIFICATION
  • HYPERTENSION
  • ASSOCIATION
  • PAZOPANIB

Cite this